Apellis Pharmaceuticals, Inc.
APLS
$41.06
$0.040.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 268.30M | 199.91M | 458.58M | 178.49M | 166.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 268.30M | 199.91M | 458.58M | 178.49M | 166.80M |
| Cost of Revenue | 117.51M | 103.95M | 92.72M | 80.64M | 120.78M |
| Gross Profit | 150.79M | 95.96M | 365.86M | 97.85M | 46.02M |
| SG&A Expenses | 124.32M | 147.10M | 142.68M | 131.14M | 129.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 241.83M | 251.06M | 235.40M | 211.78M | 250.13M |
| Operating Income | 26.47M | -51.14M | 223.18M | -33.29M | -83.33M |
| Income Before Tax | 19.15M | -58.64M | 216.32M | -41.69M | -91.88M |
| Income Tax Expenses | 496.00K | 313.00K | 602.00K | 466.00K | 341.00K |
| Earnings from Continuing Operations | 18.66M | -58.95M | 215.72M | -42.15M | -92.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.66M | -58.95M | 215.72M | -42.15M | -92.23M |
| EBIT | 26.47M | -51.14M | 223.18M | -33.29M | -83.33M |
| EBITDA | 26.76M | -50.82M | 223.52M | -32.84M | -82.88M |
| EPS Basic | 0.15 | -0.47 | 1.71 | -0.33 | -0.74 |
| Normalized Basic EPS | 0.09 | -0.29 | 1.07 | -0.21 | -0.46 |
| EPS Diluted | 0.15 | -0.49 | 1.67 | -0.33 | -0.74 |
| Normalized Diluted EPS | 0.09 | -0.29 | 1.04 | -0.21 | -0.46 |
| Average Basic Shares Outstanding | 127.68M | 126.66M | 126.42M | 126.02M | 125.45M |
| Average Diluted Shares Outstanding | 131.42M | 126.66M | 130.07M | 126.02M | 125.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |